Pharmacokinetics, safety, efficacy and immunogenicity of Adalimumab biosimilar ABP-501in rheumatoid arthritis and plaque psoriasis
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2021.
Egile nagusia: | Akter, Anika |
---|---|
Beste egile batzuk: | Alam, Marzia |
Formatua: | Thesis |
Hizkuntza: | English |
Argitaratua: |
Brac University
2022
|
Gaiak: | |
Sarrera elektronikoa: | http://hdl.handle.net/10361/17039 |
Antzeko izenburuak
-
Biologics and Biosimilars as Treatment Options for Psoriasis
nork: Moya, Amena Khatun
Argitaratua: (2023) -
Importance of biologics in rheumatoid arthritis management
nork: Riyadh, S. M.
Argitaratua: (2022) -
TNF-α inhibitor-induced alopecia in psoriatic disease patients: a pharmacovigilance study
nork: Afroza, Halima
Argitaratua: (2024) -
Importance of biologically active agents over other therapies in Rheumatoid Arthritis- a review
nork: Mehreen, Elnaj
Argitaratua: (2021) -
A pharmacovigilance study on FDA approved interleukin inhibitor-associated alopecia in the treatment of psoriasis
nork: Islam, Nahidul
Argitaratua: (2023)